other · Healthcare · Biotechnology
SYRE
88.50-0.83 -0.93%Past year
Loading chart…
Loading financials…
Company snapshot
- Ticker
- SYRE
- Exchange
- NMS
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $9.12B
- Employees
- 102
- Currency
- USD
- Website
- https://www.spyre.com
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and…
Latest coverage
No coverage yet — articles appear here automatically as press releases are published.
Related other stocks
Quotes & data
Follow Spyre Therapeutics, Inc. (SYRE) across major market-data sources.